Ino is the top holding in CNCR so that ETF must have faith in Inovio's technology. I've been a long time long with INO but it does frustrate me that moving from one clinical phase to another seems to take longer than many other biotechs.
Did something change in the company over the past few weeks other than hiring a top scientist from Merck? Or is the slide only a reflection of the market? If you still believe in this company's science and think they will deliver in the not too distant future, then nothing has changed.
I did and was encouraged by the information. The next phase III will hopefully be as positive. The lack of side effects is important since many patients discontinue taking medication because of those.
Why do you deny this basic fact? It has no bearing on the investment. Actually, it means that Inovio has been around for 35 years and that's a positive. Why don't you just sell that share you've been holding on to and move on?
I did. They were incorporated in 1979. Simply look at their profile. Then you may apologize.
Why don't investors on this board at least read the company's profile. Even a tad of due diligence would be wise.
You may be correct. At least they make money whereas many of the cyber security stocks don't. Anyway, I'll stay for awhile and see what happens. Thanks
Why do analyst downgrade or upgrade any particular stock? They are not just good neighbors they have selfish motives for sure. They want to make money and they want you to make it for them. Credit Suisse does make good chocolate and cheese. I'll give them credit for that.
Just completed 8 weeks of Harvoni. Virus not detectable at this point in time. Zero side effects. One pill per day. Some promising drugs in pipeline. New push into fatty liver disease (much larger market than Hep). Leader in HIV. Leader in Hep C. Money running out their ying yang. Guidance less than exaggerated expectations of the "street". Stock down by $5. Does it make sense. Of course not. This is market that punishes many good companies and rewards some real dogs. I'm not a day trader and have no intention of selling. If it goes down into the low to mid $90, I will buy more. Traders after hours are of no interest to me.
Initially up $2+ after beating estimates and declaring 43 cent dividend. Then down $5 because they said they would continue to do what they have been doing. I'm simply not smart enough to understand why. Gilead is not a one trick pony but apparently the "street" thinks it is. I own CELG too and they have taken a hit after posting very good quarterly results. I think perhaps I should sell these two stellar stocks and buy some dog that loses mucho money and provides nothing of benefit to humanity. Maybe it would go up.
I have three doses of Harvoni remaining on a 8 weeks treatment regime. After week 6 I had NO detectable virus. Had absolutely NO side effects. Gilead's Harvoni is FAR superior to Abbvie's considering the dosage required and the need to use Ribavirin in some cases. Harvoni is ONE pill per day! No side effects of any consequence other than maybe headaches experienced by some. I had ZERO side effects. Now that Gilead has lowered their price to be competitive with Abbvie and can not understand why any doctor would prescribe any treatment other than Harvoni.